Orange Book product · Generic (ANDA)
RIVASTIGMINE TARTRATE
RIVASTIGMINE TARTRATE
At a glance
Jun 12, 2012
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 12, 2012
14 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE TARTRATE
Strength
EQ 1.5MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 091689
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RIVASTIGMINE TARTRATE
- 2000EXELONBrand (NDA)
NDA 020823 · NOVARTIS
- 2000EXELONBrand (NDA)
NDA 021025 · NOVARTIS
- 2017RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 207797 · CHARTWELL RX
- 2017RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 203844 · CADILA PHARMS LTD
- 2016RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 204572 · AUROBINDO PHARMA
- 2015RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 090879 · ORBION PHARMS
- 2014RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 203148 · MACLEODS PHARMS LTD
- 2013RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 091072 · APOTEX INC
- 2008RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077129 · WATSON LABS
- 2007RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077130 · DR REDDYS LABS INC
- 2007RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077131 · SUN PHARM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
